3.3.2.6 (1-[2-[4-(benzooxazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)methanol - 74987 3.3.2.6 (1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)-carbamic acid tert-butyl ester - 151359 3.3.2.6 (1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)-methanol - 74994 3.3.2.6 (2R)-2-([4-[4-(thiophen-2-yl)benzyl]phenoxy]methyl)piperidine - 79197 3.3.2.6 (2R)-2-([4-[4-(thiophen-3-yl)benzyl]phenoxy]methyl)piperidine - 79182 3.3.2.6 (2R)-2-([4-[4-(thiophen-3-yl)phenoxy]phenoxy]methyl)piperidine - 79187 3.3.2.6 (2R)-2-[(4-phenoxyphenoxy)methyl]piperidine - 79029 3.3.2.6 (2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[(4-nitrobenzyl)sulfanyl]propanoic acid - 72612 3.3.2.6 (2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[(4-phenoxybenzyl)sulfanyl]propanoic acid - 72613 3.3.2.6 (2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[(4-propylbenzyl)sulfanyl]propanoic acid - 72471 3.3.2.6 (2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[[4-(trifluoromethoxy)benzyl]sulfanyl]propanoic acid - 72614 3.3.2.6 (2R)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]-3-[[4-(trifluoromethyl)benzyl]sulfanyl]propanoic acid - 72615 3.3.2.6 (2R)-2-[[4-(4-chlorobenzyl)phenoxy]methyl]piperidine - 79185 3.3.2.6 (2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-(1,2,4-oxadiazol-2(3H)-ylmethyl)piperidine - 79186 3.3.2.6 (2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidine - 79189 3.3.2.6 (2R)-2-[[4-(4-fluorophenoxy)phenoxy]methyl]piperidine - 78824 3.3.2.6 (2R)-2-[[4-(biphenyl-4-yloxy)phenoxy]methyl]piperidine - 79038 3.3.2.6 (2R)-3-(benzylsulfanyl)-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72616 3.3.2.6 (2R)-3-[(4-bromobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72617 3.3.2.6 (2R)-3-[(4-chlorobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72618 3.3.2.6 (2R)-3-[(4-cyanobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72619 3.3.2.6 (2R)-3-[(4-ethoxybenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72620 3.3.2.6 (2R)-3-[(4-ethylbenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72621 3.3.2.6 (2R)-3-[(4-fluorobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72622 3.3.2.6 (2R)-3-[(4-iodobenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72623 3.3.2.6 (2R)-3-[(4-methoxybenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72624 3.3.2.6 (2R)-3-[(4-methylbenzyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72625 3.3.2.6 (2R)-3-[(biphenyl-4-ylmethyl)sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72626 3.3.2.6 (2R)-3-[[3-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72627 3.3.2.6 (2R)-3-[[4-(1-methylethyl)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72628 3.3.2.6 (2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(3-sulfanylbutanoyl)amino]propanoic acid - 72629 3.3.2.6 (2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(3-sulfanylpropanoyl)amino]propanoic acid - 63736 3.3.2.6 (2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(4-sulfanylbutanoyl)amino]propanoic acid - 72630 3.3.2.6 (2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[(sulfanylacetyl)amino]propanoic acid - 72631 3.3.2.6 (2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2R)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 75076 3.3.2.6 (2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2R)-2-sulfanylpropanoyl]amino]propanoic acid - 75075 3.3.2.6 (2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid SA6541 75073 3.3.2.6 (2R)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-sulfanylpropanoyl]amino]propanoic acid - 75074 3.3.2.6 (2R)-3-[[4-(methoxysulfinyl)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72632 3.3.2.6 (2R)-3-[[4-(methylsulfanyl)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72633 3.3.2.6 (2S)-1-[(2R)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid 5% inhibition at 1 mM 150388 3.3.2.6 (2S)-1-[(2R)-2-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid - 150389 3.3.2.6 (2S)-2-([4-[4-(trifluoromethyl)phenoxy]phenoxy]methyl)piperidine - 78866 3.3.2.6 (2S)-2-amino-3-[4-(benzyloxy)phenyl]propane-1-thiol it are about 50 derivates and related structures synthesized and assayed their inhibition of enzyme catalyzes hxdrolysis of L-alanine-4-nitroanilide 114900 3.3.2.6 (2S)-2-amino-5-oxo-5-[(4-phenoxyphenyl)amino]-1-pentanesulfonic acid - 75882 3.3.2.6 (2S)-2-amino-N-[4-(phenylmethoxy)phenyl]-3-[4-(1H-imidazole)]propanamide dihydrochloride - 75026 3.3.2.6 (2S)-2-amino-N-[4-(phenylmethoxy)phenyl]-propanamide hydrochloride - 75021 3.3.2.6 (2S)-2-amino-N-[4-(phenylmethoxy)phenyl]benzenepropanamide hydrochloride - 75023 3.3.2.6 (2S)-2-[(4-benzylphenoxy)methyl]piperidine - 79148 3.3.2.6 (2S)-2-[(4-phenoxyphenoxy)methyl]piperidine - 78930 3.3.2.6 (2S)-2-[[4-(4-chlorobenzyl)phenoxy]methyl]piperidine - 79167 3.3.2.6 (2S)-2-[[4-(biphenyl-4-yloxy)phenoxy]methyl]piperidine - 78932 3.3.2.6 (2S)-3-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid - 72700 3.3.2.6 (2S)-4-[[4-(dimethylamino)benzyl]sulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]butanoic acid - 72702 3.3.2.6 (2S)-N-[4-(phenylmethoxy)phenyl]-2-pyrrolidinecarboxamide hydrochloride - 75024 3.3.2.6 (2S,3S)-2-amino-3-methyl-N-[4-(phenylmethoxy)-phenyl]pentanamide - 75022 3.3.2.6 (2S,4R)-3-(2-methyl-3-sulfanylpropanoyl)-2-naphthalen-1-yl-1,3-thiazolidine-4-carboxylic acid 58% inhibition at 1 mM 150423 3.3.2.6 (2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(2-phenylethyl)sulfanyl]pyrrolidine-2-carboxylic acid - 72719 3.3.2.6 (2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(3-phenylpropyl)sulfanyl]pyrrolidine-2-carboxylic acid - 72720 3.3.2.6 (2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(naphthalen-1-ylmethyl)sulfanyl]pyrrolidine-2-carboxylic acid - 72721 3.3.2.6 (2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-[(naphthalen-2-ylmethyl)sulfanyl]pyrrolidine-2-carboxylic acid - 72722 3.3.2.6 (2S,4S)-4-(benzylsulfanyl)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid - 72725 3.3.2.6 (2S,4S)-4-[(2-methylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid - 72734 3.3.2.6 (2S,4S)-4-[(3-methylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid - 72735 3.3.2.6 (2S,4S)-4-[[4-(methylsulfanyl)benzyl]sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid - 72736 3.3.2.6 (4-fluorophenyl)(pyridin-4-yl)methanone - 158792 3.3.2.6 (4R)-2-furan-2-yl-3-[(2S)-2-methyl-3-sulfanylpropanoyl]-1,3-thiazolidine-4-carboxylic acid 36% inhibition at 1 mM 150441 3.3.2.6 (4R)-3-[(2R)-2-methyl-3-sulfanylpropanoyl]-1,3-thiazolidine-4-carboxylic acid 18% inhibition at 1 mM 150442 3.3.2.6 (4R)-3-[(2S)-2-methyl-3-sulfanylpropanoyl]-1,3-thiazolidine-4-carboxylic acid 58% inhibition at 1 mM 150443 3.3.2.6 (4R)-3-[(2S)-2-methyl-3-sulfanylpropanoyl]-2-pyridin-4-yl-1,3-thiazolidine-4-carboxylic acid 25% inhibition at 1 mM 150444 3.3.2.6 (4R)-3-[(2S)-2-methyl-3-sulfanylpropanoyl]-2-thiophen-2-yl-1,3-thiazolidine-4-carboxylic acid 14% inhibition at 1 mM 146903 3.3.2.6 (4R)-4-[[4-(1-methylethyl)benzyl]sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline - 72781 3.3.2.6 (4R)-N-mercaptoacylthiazolidine-4-carboxylic acid - 151364 3.3.2.6 (4S)-4,5-diamino-N-(4-phenoxyphenyl)pentanamide - 75067 3.3.2.6 (4S)-4-([2-[4-(1-methylethyl)phenyl]ethyl]sulfanyl)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline - 72783 3.3.2.6 (4S)-4-([3-[4-(1-methylethyl)phenyl]propyl]sulfanyl)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline - 72784 3.3.2.6 (4S)-4-amino-4-(2-(1,3,4-triazolyl))-N-(4-phenoxyphenyl)butanamide trifluoroacetate - 75069 3.3.2.6 (4S)-4-amino-5-(1-phthalimido)-N-(4-phenoxyphenyl)pentanamide trifluoroacetate - 75072 3.3.2.6 (4S)-4-amino-5-(1H-pyrrol-1-yl)-N-(4-phenoxyphenyl)pentanamide bistrifluoroacetate - 75071 3.3.2.6 (4S)-4-amino-5-(2-thio-5-amino-1,3,4-thiadiazol-2-yl)-N-(4-phenoxyphenyl)pentanamide bistrifluoroacetate - 75070 3.3.2.6 (4S)-4-amino-5-hydroxy-N-(4-phenoxyphenyl)pentanamide - 39006 3.3.2.6 (4S)-4-amino-5-methoxy-N-(4-phenoxyphenyl)-pentanamide - 75068 3.3.2.6 (4S)-4-[(4-cyclohexylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline - 72787 3.3.2.6 (4S)-4-[(4-tert-butylbenzyl)sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline - 38625 3.3.2.6 (4S)-4-[[4-(1-methylethyl)benzyl]sulfanyl]-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline - 72788 3.3.2.6 (R)-2-(4-benzylphenoxymethyl)pyrrolidine - 80383 3.3.2.6 (R)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidine - 80384 3.3.2.6 (R)-2-[4-(4-thiophene-3-ylbenzoyl)phenoxymethyl]pyrrolidine - 159726 3.3.2.6 (R)-5-(1,2-dithiolan-3-yl) pentanoic acid i.e. alpha-lipoic acid, inhibits both activities of the enzyme at concentrations lower than 0.010 mM. The carboxylate group of alpha lipoic acid situates at 3 A from important residues R563 and K565 in the catalytic pocket of the protein, suggesting that alpha lipoic acid participates in electrostatic interactions with these residues 239377 3.3.2.6 (S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoic acid - 239367 3.3.2.6 (S)-2-((S)-2-(2-(((R)-1-amino-2-phenylethyl)(hydroxy)phosphoryl)acetamido)-3-phenylpropanamido)-3-phenylpropanoic acid RB3041, tight slow-binding LTA4H inhibitor 151366 3.3.2.6 (S)-2-((S)-2-(2-(((R)-1-aminoethyl)(hydroxy)phosphoryl)acetamido)-3-(biphenyl-4-yl)propanamido)propanoic acid RB3040, tight slow-binding LTA4H inhibitor 151365 3.3.2.6 1'-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl][1,4']bipiperidinyl-2-one - 74998 3.3.2.6 1,10-phenanthroline - 62 3.3.2.6 1,2-dihydroxybisabola-3,10-diene - 235773 3.3.2.6 1-(1-[2-[4-(1,3-benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)pyrrolidin-2-one - 199857 3.3.2.6 1-(1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)pyrrolidin-2-one - 74997 3.3.2.6 1-(1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-yl)pyrrolidin-2-one - 75007 3.3.2.6 1-(1-[2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenoxy]ethyl]piperidin-4-yl)pyrrolidin-2-one - 199843 3.3.2.6 1-(1-[2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenyl]ethyl]piperidin-4-yl)pyrrolidin-2-one - 199849 3.3.2.6 1-(1-[[6-(1,3-benzothiazol-2-yloxy)-1-benzofuran-3-yl]methyl]piperidin-4-yl)pyrrolidin-2-one - 199870 3.3.2.6 1-(1-[[6-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)-1-benzofuran-3-yl]methyl]piperidin-4-yl)pyrrolidin-2-one - 199871 3.3.2.6 1-(2,2'-bithiophen-5-yl)methanamine - 158843 3.3.2.6 1-(2-(4-(2-(trifluoromethyl)phenoxy)phenoxy)ethyl)pyrrolidine dual target inhibitor against cyclooxygenase COX-2 and leukotriene A4 hydrolyase in the enzyme assays and the human whole blood assay with IC50 values in the micromolar to submicromolar range. Inhibitor shows good selectivity for COX-2 over COX-1 85328 3.3.2.6 1-(2-(4-(2-nitrophenoxy)phenoxy)ethyl)pyrrolidine dual target inhibitor against cyclooxygenase COX-2 and leukotriene A4 hydrolyase in the enzyme assays and the human whole blood assay with IC50 values in the micromolar to submicromolar range. Inhibitor shows good selectivity for COX-2 over COX-1 85326 3.3.2.6 1-(2-(4-(4-chlorophenoxy)phenoxy)ethyl)pyrrolidine - 85330 3.3.2.6 1-(2-(4-(4-fluorophenoxy)phenoxy)ethyl)pyrrolidine - 85329 3.3.2.6 1-(2-(4-(4-nitrophenoxy)phenoxy)ethyl)pyrrolidine - 85327 3.3.2.6 1-(2-(4-phenoxyphenoxy)ethyl)pyrrolidine i.e. nimesulide 85325 3.3.2.6 1-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-2-[[4-(furan-2-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl]sulfanyl]ethanone compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics 165986 3.3.2.6 1-(5-[2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenoxy]ethyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)ethanone - 199845 3.3.2.6 1-(5-[2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenyl]ethyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)ethanone - 199851 3.3.2.6 1-(5-[[5-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)-1-benzofuran-3-yl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)ethanone - 199876 3.3.2.6 1-(5-[[5-([1,3]thiazolo[4,5-c]pyridin-2-yloxy)-1-benzofuran-3-yl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)ethanone - 199877 3.3.2.6 1-(5-[[5-([1,3]thiazolo[5,4-b]pyridin-2-yloxy)-1-benzofuran-3-yl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)ethanone - 199878 3.3.2.6 1-(5-[[6-(1,3-benzothiazol-2-yloxy)-1-benzofuran-3-yl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)ethanone - 199874 3.3.2.6 1-(5-[[6-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)-1-benzofuran-3-yl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)ethanone - 199875 3.3.2.6 1-(5-[[6-([1,3]thiazolo[4,5-c]pyridin-2-yloxy)-1-benzofuran-3-yl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)ethanone - 199880 3.3.2.6 1-(5-[[6-([1,3]thiazolo[5,4-b]pyridin-2-yloxy)-1-benzofuran-3-yl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)ethanone - 199881 3.3.2.6 1-([4-[(1,3-benzothiazol-2-yl)oxy]phenyl]methyl)piperidine-4-carboxylic acid i.e. JNJ-26993135 235815 3.3.2.6 1-benzyl-3-[(4-benzylphenoxy)methyl]piperazine - 79222 3.3.2.6 1-chloro-2,4-dinitrobenzene weak 182 3.3.2.6 1-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]pyrrolidin-2-one - 75014 3.3.2.6 1-[1-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)benzyl]piperidin-4-yl]pyrrolidin-2-one - 199853 3.3.2.6 1-[2-(1H-indol-5-yloxy)ethyl]piperidine-4-carboxylic acid - 159724 3.3.2.6 1-[2-[4-(benzooxazol-2-yloxy)phenoxy]ethyl]-4-phenylpiperidin-4-ol - 74988 3.3.2.6 1-[2-[4-(benzooxazol-2-yloxy)phenoxy]ethyl]piperidin-4-ol - 74986 3.3.2.6 1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]-4-phenylpiperidin-4-ol - 74995 3.3.2.6 1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-ol - 74993 3.3.2.6 1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-ylamine - 151360 3.3.2.6 1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidine-4-carboxylic acid amide - 74996 3.3.2.6 1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-ol - 75005 3.3.2.6 1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidine-4-carboxylic acid amide - 75006 3.3.2.6 1-[2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenoxy]ethyl]piperidine-4-carboxamide - 199842 3.3.2.6 1-[2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenyl]ethyl]piperidine-4-carboxamide - 199848 3.3.2.6 1-[4-(1,3-benzothiazol-2-yloxy)benzyl]piperidine-4-carboxamide - 199832 3.3.2.6 1-[4-(1,3-benzothiazol-2-yloxy)benzyl]piperidine-4-carboxylic acid JNJ-27265732 158917 3.3.2.6 1-[4-(1,3-benzothiazol-2-yloxy)benzyl]piperidine-4-carboxylic acid - 158917 3.3.2.6 1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-ol - 75012 3.3.2.6 1-[4-(benzothiazol-2-yloxy)benzyl]piperidine-4-carboxylic acid - 75019 3.3.2.6 1-[4-(benzothiazol-2-yloxy)benzyl]piperidine-4-carboxylic acid amide - 75013 3.3.2.6 1-[4-(thiophen-2-yl)phenyl]methanamine - 158942 3.3.2.6 1-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)benzyl]piperidine-4-carboxamide - 199833 3.3.2.6 1-[4-([1,3]thiazolo[5,4-b]pyridin-2-yloxy)benzyl]piperidine-4-carboxamide - 199834 3.3.2.6 1-[5-[2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenoxy]ethyl]hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]ethanone - 199844 3.3.2.6 1-[5-[2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenyl]ethyl]hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]ethanone - 199850 3.3.2.6 1-[5-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)benzyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]ethanone - 199855 3.3.2.6 1-[5-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)benzyl]hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]ethanone - 199854 3.3.2.6 1-[[6-(1,3-benzothiazol-2-yloxy)-1-benzofuran-3-yl]methyl]piperidine-4-carboxylic acid - 199866 3.3.2.6 1-[[6-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)-1-benzofuran-3-yl]methyl]piperidine-4-carboxylic acid - 199867 3.3.2.6 14,15-Leukotriene A4 - 19874 3.3.2.6 1H-indol-5-ol - 26403 3.3.2.6 2,3-Butanedione preincubation with bestatin partially protects enzyme from inactivation 1001 3.3.2.6 2,4-dimethyl-N-[[2-(thiophen-2-yl)-1,3-thiazol-4-yl]methyl]-1,3-thiazole-5-sulfonamide compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics 165992 3.3.2.6 2-(4-piperidin-1-ylmethylphenoxy)benzothiazole - 75011 3.3.2.6 2-(5-(2-(4-phenoxyphenoxy)ethoxy)-1H-indol-3-yl)ethanaminium chloride - 201305 3.3.2.6 2-(5-(3-phenoxybenzyloxy)-1H-indol-3-yl)ethanaminium chloride - 201304 3.3.2.6 2-(5-(4-phenylbenzyloxy)-1H-indol-3-yl)ethanaminium chloride - 201303 3.3.2.6 2-amino-N-[4-(phenylmethoxy)phenyl]-acetamide - 75020 3.3.2.6 2-bromo-4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid - 73027 3.3.2.6 2-fluoro-4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid - 73049 3.3.2.6 2-oxo-3-amino carboxylic esters contain a transition state mimic of the enzyme-catalyzed amide cleavage as a core and additional complementary components which resemble the hydrophobic nature of the conjugated polyene system of the natural substrate LTA4 9655 3.3.2.6 2-oxo-3-amino carboxylic esters - 9655 3.3.2.6 2-oxo-3-amino carboxylic esters comparison of inhibition of mutant and wild-type enzymes 9655 3.3.2.6 2-[(4-benzylphenoxy)methyl]piperazine - 78853 3.3.2.6 2-[(4-benzylphenoxy)methyl]piperidine - 78996 3.3.2.6 2-[(4-phenoxyphenoxy)methyl]piperidine - 79166 3.3.2.6 2-[4-(2-azepan-1-ylethoxy)phenoxy]-1H-benzoimidazole - 75002 3.3.2.6 2-[4-(2-azepan-1-ylethoxy)phenoxy]benzooxazole - 74984 3.3.2.6 2-[4-(2-azepan-1-ylethoxy)phenoxy]benzothiazole - 74991 3.3.2.6 2-[4-(2-morpholin-4-ylethoxy)phenoxy]-1-(2-trimethylsilanylethoxymethyl)-1H-benzoimidazole - 151361 3.3.2.6 2-[4-(2-morpholin-4-ylethoxy)phenoxy]-1H-benzoimidazole - 75003 3.3.2.6 2-[4-(2-morpholin-4-ylethoxy)phenoxy]benzooxazole - 74985 3.3.2.6 2-[4-(2-morpholin-4-ylethoxy)phenoxy]benzothiazole - 74992 3.3.2.6 2-[4-(2-piperidin-1-ylethoxy)phenoxy]-1H-benzoimidazole - 75001 3.3.2.6 2-[4-(2-piperidin-1-ylethoxy)phenoxy]benzooxazole - 74983 3.3.2.6 2-[4-(2-piperidin-1-ylethoxy)phenoxy]benzothiazole - 74990 3.3.2.6 2-[4-(2-piperidin-1-ylethyl)phenoxy]benzothiazole - 75004 3.3.2.6 2-[4-(2-pyrrolidin-1-ylethoxy)phenoxy]-1H-benzoimidazole - 75000 3.3.2.6 2-[4-(2-pyrrolidin-1-ylethoxy)phenoxy]benzooxazole - 74982 3.3.2.6 2-[4-(2-pyrrolidin-1-ylethoxy)phenoxy]benzothiazole - 74989 3.3.2.6 2-[4-(piperidin-1-ylmethyl)phenoxy][1,3]thiazolo[4,5-b]pyridine - 199835 3.3.2.6 2-[4-(piperidin-1-ylmethyl)phenoxy][1,3]thiazolo[4,5-c]pyridine - 199837 3.3.2.6 2-[4-(piperidin-1-ylmethyl)phenoxy][1,3]thiazolo[5,4-c]pyridine - 199836 3.3.2.6 2-[4-[2-(piperidin-1-yl)ethoxy]phenoxy][1,3]thiazolo[4,5-b]pyridine - 199841 3.3.2.6 2-[4-[2-(piperidin-1-yl)ethyl]phenoxy][1,3]thiazolo[4,5-b]pyridine - 199847 3.3.2.6 2-[4-[4-[2-[1-pyrrolidinyl]ethoxy]phenoxy]phenyl]-oxazole - 114817 3.3.2.6 2-[[2-(piperidin-1-ylmethyl)-1-benzofuran-5-yl]oxy]-1,3-benzothiazole - 199858 3.3.2.6 2-[[2-(piperidin-1-ylmethyl)-1-benzofuran-5-yl]oxy][1,3]thiazolo[4,5-b]pyridine - 199861 3.3.2.6 2-[[2-(piperidin-1-ylmethyl)-1-benzofuran-6-yl]oxy]-1,3-benzothiazole - 199859 3.3.2.6 2-[[2-(piperidin-1-ylmethyl)-1-benzofuran-6-yl]oxy][1,3]thiazolo[4,5-b]pyridine - 199862 3.3.2.6 2-[[3-(morpholin-4-ylmethyl)-1-benzofuran-6-yl]oxy]-1,3-benzothiazole - 199864 3.3.2.6 2-[[3-(morpholin-4-ylmethyl)-1-benzofuran-6-yl]oxy][1,3]thiazolo[4,5-b]pyridine - 199865 3.3.2.6 2-[[3-(piperidin-1-ylmethyl)-1-benzofuran-6-yl]oxy]-1,3-benzothiazole - 199860 3.3.2.6 2-[[3-(piperidin-1-ylmethyl)-1-benzofuran-6-yl]oxy][1,3]thiazolo[4,5-b]pyridine - 199863 3.3.2.6 2-[[4-methyl-5-([[2-oxo-2-(phenylamino)ethyl]sulfanyl]methyl)-4H-1,2,4-triazol-3-yl]sulfanyl]-N-phenylacetamide compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics 165987 3.3.2.6 2S-2,6-diamino-N-[4-(phenylmethoxy)phenyl]hexanamide dihydrochloride - 151362 3.3.2.6 3-(1-[2-[4-(benzothiazol-2-yloxy)phenoxy]ethyl]piperidin-4-yl)oxazolidin-2-one - 74999 3.3.2.6 3-(1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-yl)oxazolidin-2-one - 75008 3.3.2.6 3-(2-(5-(4-phenylbenzyloxy)-1H-indol-3-yl)ethylamino)propanoic acid - 201308 3.3.2.6 3-(4-fluorophenyl)-5-[2-methyl-5-(pyrrolidin-1-ylsulfonyl)furan-3-yl]-1,2,4-oxadiazole compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics 165988 3.3.2.6 3-(benzyloxy)pyridin-2-amine - 159014 3.3.2.6 3-amino-3,4-dihydro-1H-naphthalen-2-one O-(2-phenylethyl)oxime - 14192 3.3.2.6 3-amino-3,4-dihydro-1H-naphthalen-2-one O-(3-phenylpropyl)oxime - 14189 3.3.2.6 3-amino-3,4-dihydro-1H-naphthalen-2-one O-(4-phenylbutyl)oxime - 14190 3.3.2.6 3-amino-3,4-dihydro-1H-naphthalen-2-one O-(5-phenylpentyl)oxime - 14191 3.3.2.6 3-fluoro-4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid - 73196 3.3.2.6 3-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]propanoic acid - 79238 3.3.2.6 3-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]oxazolidin-2-one - 75015 3.3.2.6 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]-propanoic acid - 239368 3.3.2.6 3-[[4-(1-methylethyl)benzyl]sulfanyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-valine - 73225 3.3.2.6 4',5-O-dimethyl-[6]-gingerol - 236193 3.3.2.6 4'-O-acetyl shogoal - 236194 3.3.2.6 4'-O-allyl-[6]-gingerol - 236195 3.3.2.6 4'-O-methyl shogoal a potent enzyme inhibitor, non-cytotoxic to normal cells 236196 3.3.2.6 4'-O-methyl-[6]-gingerol - 236197 3.3.2.6 4'-O-prenyl-6-shagaol - 236198 3.3.2.6 4'-O-prenyl-[6]-gingerol - 236199 3.3.2.6 4-((R)-2-(4-(4-chlorophenoxy)phenoxymethyl)pyrrolidin-1-yl)-l-butyric acid - 159720 3.3.2.6 4-((S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl)-butyric acid - 80385 3.3.2.6 4-(2-amino-1,3-thiazol-4-yl)phenol - 158768 3.3.2.6 4-(4-benzylphenyl)-1,3-thiazol-2-amine i.e. ARM1 235160 3.3.2.6 4-(4-benzylphenyl)-thiazol-2-amine 4BSA 239372 3.3.2.6 4-(4-benzylphenyl)thiazol-2-amine - 201301 3.3.2.6 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide enzyme binding structure, overview 151862 3.3.2.6 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide markedly diminishes early neutrophilic inflammation in mouse models of ALI and IPF under a clinical safety dose, enzyme binding structure, overview 151862 3.3.2.6 4-([(1R,5S)-3-[(4-benzylphenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl)benzoic acid - 73251 3.3.2.6 4-([(1R,5S)-3-[(4-phenoxyphenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl)benzoic acid - 73252 3.3.2.6 4-([(2R)-2-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]pyrrolidin-1-yl]methyl)benzoic acid - 158916 3.3.2.6 4-([2-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]pyrrolidin-1-yl]methyl)benzoic acid - 38666 3.3.2.6 4-([4-[([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)methyl]piperidin-1-yl]methyl)benzoic acid - 73258 3.3.2.6 4-([methyl[2-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)ethyl]amino]methyl)benzoic acid - 73259 3.3.2.6 4-([methyl[2-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)ethyl]amino]methyl)benzoic acid - 73260 3.3.2.6 4-([methyl[3-([2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl]amino]methyl)benzoic acid - 73261 3.3.2.6 4-([methyl[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)propyl]amino]methyl)benzoic acid - 73262 3.3.2.6 4-([methyl[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)cyclohexyl]amino]methyl)benzoic acid - 73263 3.3.2.6 4-([[2,2-dimethyl-3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl](methyl)amino]methyl)benzoic acid - 73264 3.3.2.6 4-([[3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl]amino]methyl)benzoic acid - 73265 3.3.2.6 4-([[3-([2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)propyl]amino]methyl)benzoic acid - 73266 3.3.2.6 4-([[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)cyclohexyl]amino]methyl)benzoic acid - 73267 3.3.2.6 4-amino-N-[4-(benzyloxy)-phenyl]butanamide 4BS 239373 3.3.2.6 4-amino-N-[4-(phenylmethoxy)phenyl]butanamide hydrochloride - 75039 3.3.2.6 4-dimethylamino-N-[4-(phenylmethoxy)phenyl]-butanamide trifluoroacetate - 75041 3.3.2.6 4-methylamino-N-[4-(phenylmethoxy)phenyl]butanamide trifluoroacetate - 75040 3.3.2.6 4-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]butanoic acid - 78885 3.3.2.6 4-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid i.e. DG-051, a phase II clinical candidate 19211 3.3.2.6 4-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid - 19211 3.3.2.6 4-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid i.e. DG-051 19211 3.3.2.6 4-[(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid i.e. DG051 19211 3.3.2.6 4-[(2S)-2-([4-(4-chlorophenoxy)phenoxy]methyl)-1-pyrrolidinyl]butanoic acid i.e. DG-051 159719 3.3.2.6 4-[(2S)-2-([4-[4-(thiophen-3-yl)benzyl]phenoxy]methyl)piperidin-1-yl]butanoic acid - 78883 3.3.2.6 4-[(2S)-2-[[4-(4-chloro-2-hydroxyphenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid i.e. DG-051 M1-A, a derivative derived from DG-051 40211 3.3.2.6 4-[(2S)-2-[[4-(4-chloro-3-hydroxyphenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid i.e. DG-051 M1-B, a derivative derived from DG-051 40210 3.3.2.6 4-[(2S)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-oxidopyrrolidin-1-yl]butanoic acid i.e. DG-051 M2, an N-oxide derivative derived from DG-051 40224 3.3.2.6 4-[(2S)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]butanoic acid - 79217 3.3.2.6 4-[(4-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-1,4-diazepan-1-yl)methyl]benzoic acid - 73295 3.3.2.6 4-[(4-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperazin-1-yl)methyl]benzoic acid - 73296 3.3.2.6 4-[(5-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-2,5-diazabicyclo[2.2.1]hept-2-yl)methyl]benzoic acid - 73297 3.3.2.6 4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]-3-nitrobenzoic acid - 73306 3.3.2.6 4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]benzoic acid - 73307 3.3.2.6 4-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]cyclohexanecarboxylic acid - 73308 3.3.2.6 4-[(methyl[[(2R)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperidin-2-yl]methyl]amino)methyl]benzoic acid - 73309 3.3.2.6 4-[(methyl[[(2R)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]pyrrolidin-2-yl]methyl]amino)methyl]benzoic acid - 73310 3.3.2.6 4-[(methyl[[(2S)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperidin-2-yl]methyl]amino)methyl]benzoic acid - 73311 3.3.2.6 4-[(methyl[[(2S)-1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]pyrrolidin-2-yl]methyl]amino)methyl]benzoic acid - 73312 3.3.2.6 4-[2-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)ethyl]benzoic acid - 73323 3.3.2.6 4-[2-[(1R,5S)-3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]benzoic acid - 73324 3.3.2.6 4-[2-[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]ethyl]benzoic acid - 73325 3.3.2.6 4-[2-[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]ethyl]benzoic acid - 73326 3.3.2.6 4-[[(1R,5S)-3-([4-[3-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid JNJ-26993135 158809 3.3.2.6 4-[[(1R,5S)-3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73332 3.3.2.6 4-[[(1R,5S)-3-([4-[4-(1,3-thiazol-2-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73333 3.3.2.6 4-[[(1R,5S)-3-([4-[4-(1H-pyrrol-1-yl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73334 3.3.2.6 4-[[(1R,5S)-3-([4-[4-(trifluoromethyl)phenoxy]phenyl]amino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73335 3.3.2.6 4-[[(1R,5S)-3-[[4-(1,3-benzothiazol-2-yloxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73336 3.3.2.6 4-[[(1R,5S)-3-[[4-(2-chlorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73337 3.3.2.6 4-[[(1R,5S)-3-[[4-(2-fluorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73338 3.3.2.6 4-[[(1R,5S)-3-[[4-(4-chlorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73339 3.3.2.6 4-[[(1R,5S)-3-[[4-(4-fluorophenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73340 3.3.2.6 4-[[(1R,5S)-3-[[4-(4-methoxyphenoxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73341 3.3.2.6 4-[[(1R,5S)-3-[[4-(benzyloxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73342 3.3.2.6 4-[[(1R,5S)-3-[[4-(biphenyl-4-yloxy)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73343 3.3.2.6 4-[[(1R,5S)-3-[[4-(pyridin-4-ylmethyl)phenyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]methyl]benzoic acid - 73344 3.3.2.6 4-[[(3-[[2-([4-[(2R)-2-hydroxy-2-phenylethoxy]phenyl]amino)-2-oxoethyl](methyl)amino]propyl)(methyl)amino]methyl]benzoic acid - 73346 3.3.2.6 4-[[(3R)-3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)pyrrolidin-1-yl]methyl]benzoic acid - 73347 3.3.2.6 4-[[(3S)-3-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)pyrrolidin-1-yl]methyl]benzoic acid - 73348 3.3.2.6 4-[[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]methyl]benzoic acid - 73350 3.3.2.6 4-[[3-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)pyrrolidin-1-yl]methyl]benzoic acid - 73351 3.3.2.6 4-[[4-(1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]hydrazino)piperidin-1-yl]methyl]benzoic acid - 73352 3.3.2.6 4-[[4-(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)azepan-1-yl]methyl]benzoic acid - 73353 3.3.2.6 4-[[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)azepan-1-yl]methyl]benzoic acid - 73354 3.3.2.6 4-[[4-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)piperidin-1-yl]methyl]benzoic acid - 73355 3.3.2.6 4-[[methyl(1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]azepan-4-yl)amino]methyl]benzoic acid - 73358 3.3.2.6 4-[[methyl(1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]piperidin-4-yl)amino]methyl]benzoic acid - 73359 3.3.2.6 4-[[methyl(3-[methyl[2-([4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]amino)-2-oxoethyl]amino]propyl)amino]methyl]benzoic acid - 73360 3.3.2.6 4-[[[3-[(2-[[4-(2-fluorophenoxy)phenyl]amino]-2-oxoethyl)(methyl)amino]propyl](methyl)amino]methyl]benzoic acid - 73361 3.3.2.6 4-[[[3-[(2-[[4-(4-chlorophenoxy)phenyl]amino]-2-oxoethyl)(methyl)amino]propyl](methyl)amino]methyl]benzoic acid - 73362 3.3.2.6 4-[[[3-[(2-[[4-(4-fluorophenoxy)phenyl]amino]-2-oxoethyl)(methyl)amino]propyl](methyl)amino]methyl]benzoic acid - 73363 3.3.2.6 4-[[[3-[[2-[(4-benzylphenyl)amino]-2-oxoethyl](methyl)amino]propyl](methyl)amino]methyl]benzoic acid - 73364 3.3.2.6 5-(2-pyrrolidin-1-ylethoxy)-1H-indole - 159723 3.3.2.6 5-chloro-1H-indole - 158779 3.3.2.6 5-fluoro-1H-indole - 158990 3.3.2.6 5-hydroxytryptamine - 1669 3.3.2.6 5-O-methyl-[6]-gingerol - 236304 3.3.2.6 5-oxo-5-[[4-(phenylmethoxy)phenyl]amino]pentanoic acid - 75034 3.3.2.6 5-[(methyl[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]amino)methyl]furan-2-carboxylic acid - 73424 3.3.2.6 6-chloro-2-[4-(piperidin-1-ylmethyl)phenoxy][1,3]thiazolo[4,5-b]pyridine - 199839 3.3.2.6 6-fluoro-2-[4-(piperidin-1-ylmethyl)phenoxy][1,3]thiazolo[4,5-b]pyridine - 199840 3.3.2.6 7,11-trans-9-cis-Leukotriene A4 - 92071 3.3.2.6 7-methyl-2-[4-(piperidin-1-ylmethyl)phenoxy][1,3]thiazolo[4,5-b]pyridine - 199838 3.3.2.6 7-trans-9,11-cis-Leukotriene A4 - 92094 3.3.2.6 8-Hydroxy-quinoline-5-sulfonic acid - 92138 3.3.2.6 abexinostat - 236350 3.3.2.6 acetic acid (1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-ylcarbamoyl)methyl ester - 75010 3.3.2.6 acetic acid [1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-ylcarbamoyl]methyl ester - 75017 3.3.2.6 Acetic anhydride complete loss of peptidase activity and epoxide hydrolase activity 3322 3.3.2.6 acrolein acrolein in cigarette smoke in part inhibits LTA4H peptidase activity 1198 3.3.2.6 aminohydroxamic acid - 67239 3.3.2.6 ammonium sulfate - 1058 3.3.2.6 ARM1 - 239374 3.3.2.6 belinostat - 151865 3.3.2.6 benzyl[4-((R)-1-pyrrolidin-2-ylmethoxy)phenyl]amine - 159722 3.3.2.6 bestatin immediate and reversible effect on isolated enzyme 225 3.3.2.6 bestatin - 225 3.3.2.6 bestatin no influence 225 3.3.2.6 bestatin aminopeptidase activity, leukotriene A4 competes partially 225 3.3.2.6 bestatin comparison of inhibition of mutant and wild-type enzymes, mechanism 225 3.3.2.6 bestatin bestatin inhibits leukotriene B4 biosynthesis in the esophageal tissues 225 3.3.2.6 bestatin isolated from Streptomyces olivoreticuli, a general AP inhibitor, inhibits LTB4 biosynthesis. Treatment with bestatin inhibits cell proliferation of lung carcinoma A549 cells by significantly reducing LTA4H activity 225 3.3.2.6 bestatin isolated from Streptomyces olivoreticuli, a general AP inhibitor, inhibits LTB4 biosynthesis. Following a short-term intraperitoneal treatment with 10 mg/kg bestatin, LTB4 biosynthesis in the esophagoduodenal junction is significantly suppressed in rats treated with EGDA compared to that in the untreated group, in an esophagogastroduodenal anastomosis (EGDA) surgical model. Bestatin inhibits LTA4H/LTB4 activation and reduces tumorigenesis in EGDA rats 225 3.3.2.6 bestatin significantly inhibits LTB4 production, samples from13 CRC patients show a significant decrease in LTB4, the LTA4H signaling pathway, and Ki-67 in the bestatin-treated group compared with the untreated group 225 3.3.2.6 bestatin significantly inhibit LTB4 production, bestatin effectively inhibits LTB4 synthesis and tumorigenesis in the ApcMin/+ and CRC patient-derived xenograft mouse model 225 3.3.2.6 bis-(I-5'->II-5')-[6]-gingerol - 236361 3.3.2.6 captopril - 469 3.3.2.6 captopril 59% inhibition at 1 mM 469 3.3.2.6 Cd2+ - 52 3.3.2.6 citraconic anhydride complete loss of peptidase activity and epoxide hydrolase activity 6771 3.3.2.6 Co2+ - 23 3.3.2.6 Co2+ reversible by addition of EDTA 23 3.3.2.6 Cu2+ - 19 3.3.2.6 CUDC-101 - 236365 3.3.2.6 DELTA8-[10]-gingerol - 236373 3.3.2.6 DG-051 - 74981 3.3.2.6 DG-051 a LTA4H inhibitor, used for therapeutic modulation of the leukotriene synthesis pathway in case of myocardial infarction 74981 3.3.2.6 diacetyl-[6]-gingerol - 236375 3.3.2.6 diamide/glutathione combination complete loss of peptidase activity and epoxide hydrolase activity 115554 3.3.2.6 dihydroresveratrol - 159721 3.3.2.6 entinostat - 151866 3.3.2.6 givinostat - 236441 3.3.2.6 HgCl2 - 110 3.3.2.6 hydroxamic acid aminopeptidase activity 9542 3.3.2.6 hydroxamic acid comparison of inhibition of mutant and wild-type enzymes 9542 3.3.2.6 hydroxamic acid - 9542 3.3.2.6 iodoacetamide weak 67 3.3.2.6 iodoacetic acid weak 213 3.3.2.6 JMC08-4 i.e. 1,2-amino-3-[5-(benzyloxy)-1H-indol-3-yl] propanoic acid 201302 3.3.2.6 JNJ 26993135 a selective LTA4H inhibitor, leads to reduction of TH2 cytokines and mucin levels, and blocks mast cell production of LTB4 and suppresses airway hyperresponsiveness 159717 3.3.2.6 JNJ 40929837 - 239369 3.3.2.6 JNJ-26481585 - 151847 3.3.2.6 JNJ-26993135 shows selective inhibition of LTB4 biosynthesis in a murine model, suggesting a potent compound targeting LTA4H 239371 3.3.2.6 KCl - 79 3.3.2.6 Kelatorphan - 10684 3.3.2.6 Leu-thiol - 96724 3.3.2.6 leukotriene A4 - 807 3.3.2.6 leukotriene A4 suicide inactivation 807 3.3.2.6 leukotriene A4 suicide inactivation via an apparently mechanism-based irreversible binding of leukotriene A4 to the protein in a 1:1 stoichiometry, comparison of inactivation of wild-type and mutant enzymes, Tyr378 is a residue, which is involved in the binding of leukotriene A4 807 3.3.2.6 leukotriene A4 comparison of inactivation of wild-type and mutant enzymes; suicide inactivation 807 3.3.2.6 leukotriene A4 leukotriene A4 binds covalently to Tyr378 and blocks epoxide hydrolase and aminopeptidase activities 807 3.3.2.6 leukotriene A4 inhibits epoxid hydrolase activity and stimulates peptidase activity 807 3.3.2.6 leukotriene A4 pre-treatment of enzyme by methyl-methane thiosulfonate does not protect against suicide inactivation by leukotriene A4 807 3.3.2.6 leukotriene A4 ethyl ester comparison of inactivation of wild-type and mutant enzymes 115967 3.3.2.6 leukotriene A4 methyl ester - 2490 3.3.2.6 leukotriene A4 methyl ester comparison of inactivation of wild-type and mutant enzymes 2490 3.3.2.6 leukotriene A4 methyl ester no influence 2490 3.3.2.6 Leukotriene A5 - 20358 3.3.2.6 methyl 3-(2-(5-(3-phenoxybenzyloxy)-1H-indol-3-yl)ethylamino)propanoate - 201307 3.3.2.6 methyl 3-(2-(5-(4-phenylbenzyloxy)-1H-indol-3-yl)ethylamino)propanoate - 201306 3.3.2.6 methyl 5-(1,2-dithiolan-3-yl) pentanoate i.e. alpha-lipoic acid methyl ester or LAME 236464 3.3.2.6 methyl methanethiosulfonate inhibition of epoxide hydrolase activity, stimulation of peptidase activity 2346 3.3.2.6 methyl shogoal a [6]-gingerol derivative 239370 3.3.2.6 methyl zingerone - 236467 3.3.2.6 methyl-methane thiosulfonate inhibits aminopeptidase activity and NaCl stimulates this inactivation, beta-mercaptoethanol reactivates this inactivation, bestatin protects inactivation, little effect on epoxid hydrolase activity 114627 3.3.2.6 methyl-N-[3-[4-(phenylmethyl)-phenoxy]propyl]-beta-alanine - 116075 3.3.2.6 mocetinostat - 205464 3.3.2.6 additional information not: EDTA, dipicolinic acid 2 3.3.2.6 additional information not diethyl dicarbonate 2 3.3.2.6 additional information some enzyme inhibitors also affect the cytotoxicity of the anthrax lethal factor on macrophage cell lines 2 3.3.2.6 additional information not: PMSF, GEMSA, iodoacetamide 2 3.3.2.6 additional information leukotriene A4 inhibitors based on piperidine and piperazine scaffolds, overview 2 3.3.2.6 additional information structure-based drug discovery, inhibitor binding and molecular docking, overview 2 3.3.2.6 additional information inhibitor structure-function analysis, overview 2 3.3.2.6 additional information combined molecular docking and pharmacophore filtering assay for identification of chemical compounds that can simultaneously inhibit the human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S enzymes 2 3.3.2.6 additional information not inhibited by NI101, 2-(5-(benzyloxy)-1H-indol-3-yl)ethanaminium chloride, 2-(5-(naphthalen-2-ylmethoxy)-1H-indol-3-yl)ethanaminiumchloride, 2-(5-(naphthalen-1-ylmethoxy)-1H-indol-3-yl)ethanaminium chloride, 2-(5-(3-phenoxybenzyloxy)-1H-indol-3-yl)ethanaminium chloride, 2-(5-(2-(4-(4-nitrophenoxy)phenoxy)ethoxy)-1H-indol-3-yl)ethanaminium chloride, 2-(5-(2-(4-(2-nitrophenoxy)phenoxy)ethoxy)-1H-indol-3-yl) ethanaminium chloride, 3-(2-(5-(3-phenoxybenzyloxy)-1H-indol-3-yl)ethylamino)propanoic acid, and 3-(2-(5-(2-(4-phenoxyphenoxy)ethoxy)-1H-indol-3-yl) ethylamino)propanoic acid 2 3.3.2.6 additional information cigarette smoke exposure acidifies the airspaces and induced localization of the LTA4H protein into the nuclei of the epithelial cells. This results in accumulation of proline-glycine-proline in the airspaces by suppressing the LTA4H aminopeptidase activity 2 3.3.2.6 additional information tosedostat, or CHR-2797 shows inhibition of the aminopeptidase activity. [6]-Gingerol and derivatives show chemopreventive effects and selective cytotoxicity toward HCT-116 cells but not toward healthy cells 2 3.3.2.6 additional information treatment with bestatin does not inhibit cell proliferation of NIH/3T3 normal mouse embryo fibroblast cells 2 3.3.2.6 additional information thermodynamic properties of structurally distinct leukotriene A4 hydrolase inhibitors. An in silico method for the determination of stabilized water molecules in the binding site of the apo structure of LTA4H is used to interpret the measured thermodynamic data and provided insights for design of novel LTA4H inhibitors. Fluorescence-based assay system with recombinant His6-tagged enzyme is used for determination of the inhibition kinetics 2 3.3.2.6 additional information synthesis, docking, cytotoxicity, and LTA4H inhibitory activity of gingerol derivatives as potential colorectal cancer therapy. NMR spectroscopic structure analysis, enzyme-inhibitor interactions, molecular modeling and docking study, overview. IC50 for cytotoxicity with HCT-116, TIG-1, and HF-1 cells 2 3.3.2.6 additional information 5-lipoxygenase inhibitor zileuton, or the 5-lipoxygenase activating protein inhibitor MK-886, are unable to inhibit the activity of the enzyme. Inhibitor docking and molecular dynamics simulations, interaction analysis 2 3.3.2.6 additional information drug repurposing of histone deacetylase (HDAC) inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis, overview. Analysis of potential inhibitors of LTA4H across a panel of 18 HDAC inhibitors, using enzymatic assay, thermofluor assay, and X-ray crystallographic investigation. Detailed mechanisms of down-regulation of proinflammatory cytokines by SAHA or M344 are determined in vivo. Cotreatment of N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-methylbenzamide and (S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoic acid synergistically represses the migration of neutrophil and LTB4-induced neutrophil migration is not affected by these treatments. Molecular modelling of HDAC inhibitors against LTA4H hydrolase and aminopeptidase 2 3.3.2.6 additional information drug repurposing of histone deacetylase (HDAC) inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis, overview. Analysis of potential inhibitors of LTA4H across a panel of 18 HDAC inhibitors, using enzymatic assay, thermofluor assay, and X-ray crystallographic investigation. Detailed mechanisms of down-regulation of proinflammatory cytokines by SAHA or M344 are determined in vivo. Cotreatment of N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-methylbenzamide and (S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoic acid synergistically represses the migration of neutrophil and LTB4-induced neutrophil migration is not affected by these treatments. Molecular modeling of HDAC inhibitors against LTA4H hydrolase and aminopeptidase 2 3.3.2.6 N-(1-[2-[4-(benzothiazol-2-yloxy)phenyl]ethyl]piperidin-4-yl)acetamide - 75009 3.3.2.6 N-(1-[[6-(1,3-benzothiazol-2-yloxy)-1-benzofuran-3-yl]methyl]piperidin-4-yl)acetamide - 199868 3.3.2.6 N-(1-[[6-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)-1-benzofuran-3-yl]methyl]piperidin-4-yl)acetamide - 199869 3.3.2.6 N-(2-[[6-(4-fluorophenyl)pyridazin-3-yl]amino]ethyl)-1,2-dimethyl-1H-imidazole-4-sulfonamide compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics 165991 3.3.2.6 N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-methylbenzamide - 236667 3.3.2.6 N-(8-[2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenoxy]ethyl]-8-azabicyclo[3.2.1]oct-3-yl)acetamide - 199846 3.3.2.6 N-(8-[2-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)phenyl]ethyl]-8-azabicyclo[3.2.1]oct-3-yl)acetamide - 199852 3.3.2.6 N-Acetylimidazole 75 min, loss of 92% peptidase activity and 78% of epoxide hydrolase activity, both activities are restored by hydroxylamine and bestatin protects 1559 3.3.2.6 N-ethylmaleimide - 49 3.3.2.6 N-ethylmaleimide weak 49 3.3.2.6 N-mercaptoacyl-L-proline - 151363 3.3.2.6 N-methyl-1-[2-(thiophen-2-yl)phenyl]methanamine - 158832 3.3.2.6 N-[(3-endo)-8-[[6-(1,3-benzothiazol-2-yloxy)-1-benzofuran-3-yl]methyl]-8-azabicyclo[3.2.1]oct-3-yl]acetamide - 199872 3.3.2.6 N-[(3-endo)-8-[[6-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)-1-benzofuran-3-yl]methyl]-8-azabicyclo[3.2.1]oct-3-yl]acetamide - 199873 3.3.2.6 N-[1-[4-(1,3-benzothiazol-2-yloxy)benzyl]piperidin-4-yl]-2-hydroxyacetamide SC-57461A 158839 3.3.2.6 N-[1-[4-(1,3-benzothiazol-2-yloxy)benzyl]piperidin-4-yl]-2-hydroxyacetamide - 158839 3.3.2.6 N-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]-2-hydroxyacetamide - 75018 3.3.2.6 N-[1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-yl]acetamide - 75016 3.3.2.6 N-[2-[(furan-2-ylmethyl)sulfanyl]ethyl]-2-[[1-(4-hydroxyphenyl)-1H-tetrazol-5-yl]sulfanyl]acetamide compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics 165990 3.3.2.6 N-[3(R)-[(hydroxyamino)carbonyl]-2-benzyl-1-oxopropyl]-L-alanine i.e. kelatorphan, potent inhibitor of Zn-metalloenzymes 85324 3.3.2.6 N-[3-(4-benzylphenoxy)propyl]-N-methyl-beta-alanine SA-6541 159718 3.3.2.6 N-[3-(4-benzylphenoxy)propyl]-N-methyl-beta-alanine i.e. SC-57461A 159718 3.3.2.6 N-[3-[3-(acetylamino)phenoxy]propyl]-3-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]propanamide compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics 165985 3.3.2.6 N-[4-(3-chlorophenyl)-2,5-dioxopiperazin-1-yl]-2-[[4-methyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl]acetamide compound identified by pharmacophore modeling, binds both human leukotriene hydrolase hLTA4H and the human leukotriene C4 synthase hLTC4S with good binding characteristics 165989 3.3.2.6 N-[8-[4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)benzyl]-8-azabicyclo[3.2.1]oct-3-yl]acetamide - 199856 3.3.2.6 N1-(2-aminoethyl)-N5-(4-phenoxyphenyl)-L-glutamamide hydrochloride - 75066 3.3.2.6 N1-(2-carboxyethyl)-N5-(4-phenoxyphenyl)-L-glutamamide trifluoroacetate - 75062 3.3.2.6 N1-(2-hydroxyethyl)-N5-(4-phenoxyphenyl)-L-glutamamide trifluoroacetate - 75065 3.3.2.6 N1-(3-carboxypropyl)-N5-(4-phenoxyphenyl)-L-glutamamide trifluoroacetate - 75063 3.3.2.6 N1-(4-carboxybutyl)-N5-(4-phenoxyphenyl)-L-glutamamide bistrifluoroacetate - 75064 3.3.2.6 N1-hydroxy-N5-[4-(phenylmethoxy)phenyl]-L-glutamamide trifluoroacetate - 75038 3.3.2.6 N1-[4-(phenylmethoxy)phenyl]-D-aspartamine - 75030 3.3.2.6 N1-[4-(phenylmethoxy)phenyl]-D-glutamine trifluoroacetate - 75029 3.3.2.6 N1-[4-(phenylmethoxy)phenyl]-L-aspartamine trifluoroacetate - 75028 3.3.2.6 N1-[4-(phenylmethoxy)phenyl]-L-glutamamide hydrochloride - 75025 3.3.2.6 N1-[4-(phenylmethoxy)phenyl]-L-glutamine trifluoroacetate - 75027 3.3.2.6 N2-methyl-N-(4-phenoxyphenyl)-N2-[4-(1H-tetrazol-5-yl)benzyl]glycinamide - 73785 3.3.2.6 N2-methyl-N2-[3-[methyl(4-oxobutyl)amino]propyl]-N-(4-phenoxyphenyl)glycinamide - 73786 3.3.2.6 N2-methyl-N2-[4-[methyl(4-oxobutyl)amino]butyl]-N-(4-phenoxyphenyl)glycinamide - 73787 3.3.2.6 N2-[3-(dimethylamino)propyl]-N2-methyl-N-(4-phenoxyphenyl)glycinamide - 73789 3.3.2.6 N2-[3-[benzyl(methyl)amino]propyl]-N2-methyl-N-(4-phenoxyphenyl)glycinamide - 72499 3.3.2.6 N2-[4-[(aminooxy)sulfinyl]benzyl]-N2-methyl-N-(4-phenoxyphenyl)glycinamide - 73790 3.3.2.6 N4-[4-(phenylmethoxy)phenyl]-L-aspartamine trifluoroacetate - 75031 3.3.2.6 N5-(4-phenoxyphenyl)-L-glutamine - 75046 3.3.2.6 N5-phenyl-L-glutamamide dihydrochloride - 75042 3.3.2.6 N5-[(4-phenoxy)-3-pyridyl]-L-glutamamide tristrifluoroacetate - 75045 3.3.2.6 N5-[3-(phenylmethoxy)phenyl]-L-glutamine methyl ester - 75044 3.3.2.6 N5-[4-(1H-pyrrol-1-yl)phenyl]-L-glutamamide hydrochloride - 75043 3.3.2.6 N5-[4-(2-hydroxy-3-phenylpropoxy)phenyl]-L-glutamine trifluoroacetate - 75053 3.3.2.6 N5-[4-(2-methylphenoxy)phenyl]-L-glutamamide hydrochloride - 75056 3.3.2.6 N5-[4-(2-oxo-3-phenylpropoxy)phenyl]-L-glutamine trifluoroacetate - 75052 3.3.2.6 N5-[4-(2-phenylethoxy)phenyl]-L-glutamine - 75050 3.3.2.6 N5-[4-(3-methylphenoxy)phenyl]-L-glutamamide hydrochloride - 75057 3.3.2.6 N5-[4-(3-phenylpropoxy)phenyl]-L-glutamine - 75051 3.3.2.6 N5-[4-(4-(3-furyl)phenoxy)phenyl]-L-glutamamide trifluoroacetate - 75060 3.3.2.6 N5-[4-(4-methylphenoxy)phenyl]-L-glutamamide hydrochloride - 75058 3.3.2.6 N5-[4-(cyclohexyloxy)phenyl]-L-glutamamide - 75055 3.3.2.6 N5-[4-(N-methyl-N-phenylamino)phenyl]-L-glutamine methyl ester trifluoroacetate - 75049 3.3.2.6 N5-[4-(N-phenylamino)phenyl]-L-glutamine bistrifluoroacetate - 75048 3.3.2.6 N5-[4-(phenylmethoxy)phenyl]-D-glutamine hydrochloride - 75033 3.3.2.6 N5-[4-(phenylmethoxy)phenyl]-L-glutamamide trifluoroacetate - 75037 3.3.2.6 N5-[4-(phenylmethoxy)phenyl]-L-glutamine 1,1-dimethylethyl ester - 75036 3.3.2.6 N5-[4-(phenylmethoxy)phenyl]-L-glutamine hemitrifluoroacetate - 75032 3.3.2.6 N5-[4-(phenylmethoxy)phenyl]-L-glutamine methyl ester hydrochloride - 75035 3.3.2.6 N5-[4-benzylphenyl]-L-glutamamide trifluoroacetate - 75047 3.3.2.6 N5-[4-methoxyphenyl]-L-glutamine methyl ester trifluoroacetate - 75054 3.3.2.6 N5-[4-[4-(1H-pyrrol-1-yl)phenoxy]phenyl]-L-glutamine hemitrifluoroacetate - 75059 3.3.2.6 N6-[4-(4-methylphenoxy)phenyl]-L-homoglutamine trifluoroacetate - 75061 3.3.2.6 Ni2+ - 38 3.3.2.6 o-phenanthroline - 239 3.3.2.6 omega-[(omega-arylalkyl)aryl]alkanoid acids - 116309 3.3.2.6 p-hydroxymercuribenzoate bestatin protects inactivation 98 3.3.2.6 panobinostat - 163471 3.3.2.6 PCMB - 78 3.3.2.6 Phenylglyoxal preincubation with captopril protects enzyme from inactivation 301 3.3.2.6 pracinostat - 237054 3.3.2.6 puromycin - 657 3.3.2.6 pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol - 159725 3.3.2.6 RB-3014 - 25210 3.3.2.6 RB202 - 239375 3.3.2.6 resminostat - 205844 3.3.2.6 resveratrol - 799 3.3.2.6 resveratrol binds directly to LTA4H and inhibits its activity. The antiproliferative effect of resveratrol is decreased in LTA4H mRNA knockdown cells, LTA4H is a direct target of resveratrol 799 3.3.2.6 rocilinostat - 237058 3.3.2.6 S-(4-cyclohexylbenzyl)-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 38716 3.3.2.6 S-(4-tert-butylbenzyl)-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73808 3.3.2.6 S-[(4-cyclohexylphenyl)(phenyl)methyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73809 3.3.2.6 S-[1-(4-cyclohexylphenyl)-1-methylethyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73810 3.3.2.6 S-[1-methyl-1-[4-(1-methylethyl)phenyl]ethyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73811 3.3.2.6 S-[1-[4-(1-methylethyl)phenyl]butyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73812 3.3.2.6 S-[1-[4-(1-methylethyl)phenyl]ethyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73813 3.3.2.6 S-[1-[4-(1-methylethyl)phenyl]pentyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73814 3.3.2.6 S-[1-[4-(1-methylethyl)phenyl]propyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73815 3.3.2.6 S-[2-methyl-1-[4-(1-methylethyl)phenyl]propyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73817 3.3.2.6 S-[4-(diethylamino)benzyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73819 3.3.2.6 S-[4-(dimethylamino)benzyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine i.e. SA6541, a specific inhibiter of LTA4 hydrolase, that attenuates 5-lipoxygenase metabolite-induced scratching behavior, but does not affect the increase in vascular permeability caused by 5-hydroperoxyeicosatetraenoic acid, 5-HPETE, overview 159727 3.3.2.6 S-[[4-(1-methylethyl)phenyl](phenyl)methyl]-N-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-cysteine - 73820 3.3.2.6 SA6541 - 141800 3.3.2.6 SA6541 inhibits LTA4H activation 141800 3.3.2.6 SC-57461A - 74980 3.3.2.6 SC-57461A i.e. N-[3-(4-benzylphenoxy)propyl]-N-methyl-beta-L-alanine 74980 3.3.2.6 SC57461A - 239376 3.3.2.6 scriptaid - 163467 3.3.2.6 suberanilohydroxamic acid enzyme binding structure, overview 237067 3.3.2.6 suberanilohydroxamic acid markedly diminishes early neutrophilic inflammation in mouse models of ALI and IPF under a clinical safety dose, enzyme binding structure, overview 237067 3.3.2.6 sulindac sulfide reduces LTA4H activity in HT29 CRC cells, thus lowering LTB4 levels and decreasing HT29 cell viability 3533 3.3.2.6 Tetranitromethane preincubation with bestatin prevents the inactivation 1453 3.3.2.6 thioamine - 8504 3.3.2.6 thioamine aminopeptidase activity, leukotriene A4 restores 8504 3.3.2.6 thioamine comparison of inhibition of mutant and wild-type enzymes 8504 3.3.2.6 trichostatin A - 1314 3.3.2.6 Trinitrobenzenesulfonate complete loss of peptidase activity and epoxide hydrolase activity 6028 3.3.2.6 tubacin - 26695 3.3.2.6 Valproate - 6032 3.3.2.6 Zn2+ - 14 3.3.2.6 Zn2+ reversible by addition of EDTA 14 3.3.2.6 [(2R)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]piperidin-1-yl]acetic acid - 79101 3.3.2.6 [10]-gingerol - 237179 3.3.2.6 [4]-gingerol - 237196 3.3.2.6 [6]-gingerol from ginger, [6]-gingerol suppresses anchorage-independent cancer cell growth by inhibiting LTA4H activity in HCT116 colorectal cancer cells, overview. [6]-Gingerol specifically binds with LTA4H in vitro and ex vivo 63483 3.3.2.6 [6]-gingerol from ginger, [6]-gingerol suppresses anchorage-independent cancer cell growth by inhibiting LTA4H activity in mice, overview. [6]-Gingerol specifically binds with LTA4H in vitro and ex vivo 63483 3.3.2.6 [6]-gingerol - 63483 3.3.2.6 [6]-shogaol - 237204 3.3.2.6 [8]-gingerol - 237205